Merck Sharp and Dohme NZ have removed their two year limit of free treatment under their Keytruda immunotherapy cost share programme for bowel cancer patients.
Keytruda cost share treatment was previously capped by the pharmaceutical company who makes it, for up to two years, where it was deemed the drug should have worked sufficiently to reduce tumours and the patient remains stable or presents with no evidence of disease.
In December 2019 the rules were revised by Merck Sharp and Dohme NZ to allow the patient access to the treatment for as long as they require it as part of their cost share programme that helps make the drug more affordable.
Keytruda is an immunotherapy drug that works particularly well for Lynch Syndrome patients but carries a hefty price tag and because it is unfunded, The Ministry of Health requires it to be administered in a private oncology centre.
Cost Share Programmes may offer free treatment doses or a capped payment for the duration of treatment. Always involve your Doctor/oncologist to work out which immunotherapy treatment could be right for you as Keytruda works better in some patients and Avastin made by Roche, in others.
To read more about cost share programmes click here
To read Jack's Keytruda story click here